Epidemiology of the Metabolic Syndrome and Risk for Cardiovascular Disease and Diabetes

  • Adrian Cameron
  • Jonathan Shaw


The metabolic syndrome and diabetes have been increasing in prevalence worldwide since at least the middle of the 20th century, and it appears that this trend is continuing into the new millennium. Diabetes is one of the most common noncommunicable diseases globally and is the fourth or fifth leading cause of death in most developed countries. The global prevalence was estimated to be 5.9% in 2007, representing almost 250 million people, of whom 80% live in developing countries—despite type 2 diabetes and the metabolic syndrome often being perceived as resulting from a “Western” lifestyle. Projections suggest that this number will approach 400 million by 2025.


Metabolic Syndrome Peripheral Arterial Disease Impaired Fasting Glucose Cardiometabolic Risk Strong Risk Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Grundy SM: Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 2006, 5:295–309.CrossRefPubMedGoogle Scholar
  2. 2.
    Cameron AJ, Shaw JE, Zimmet PZ: The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004, 33:351–376.CrossRefPubMedGoogle Scholar
  3. 3.
    He Y, Jiang B, Wang J, et al.: Prevalence of the metabolic syndrome and its relation to cardiovascular disease in an elderly Chinese population. J Am Coll Cardiol 2006, 47:1588–1594.CrossRefPubMedGoogle Scholar
  4. 4.
    Cameron AJ, Magliano DJ, Zimmet PZ, et al.: The metabolic syndrome in Australia: prevalence using four definitions. Diabetes Res Clin Pract 2007, 77:471–478.CrossRefPubMedGoogle Scholar
  5. 5.
    Cameron AJ, Zimmet PZ, Soderberg S, et al.: The metabolic syndrome as a predictor of incident diabetes mellitus in Mauritius. Diabet Med 2007, 24:1460–1469.CrossRefPubMedGoogle Scholar
  6. 6.
    Cameron AJ, Boyko EJ, Sicree RA, et al.: Central obesity as a precursor to the metabolic syndrome in the AusDiab study and Mauritius. Obesity 2008, 16:2707–2716.CrossRefPubMedGoogle Scholar
  7. 7.
    Yudkin JS: Insulin resistance and the metabolic syndrome: or the pitfalls of epidemiology. Diabetologia 2007, 50:1576–1586.CrossRefPubMedGoogle Scholar
  8. 8.
    Lloyd-Jones DM, Liu K, Colangelo LA, et al.: Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the Coronary Artery Risk Development in Young Adults Study. Circulation 2007, 115:1004–1011.CrossRefPubMedGoogle Scholar
  9. 9.
    Laaksonen DE, Niskanen L, Nyyssonen K, et al.: C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004, 47:1403–1410.CrossRefPubMedGoogle Scholar
  10. 10.
    Rutter MK, Meigs JB, Wilson PW: Cardiovascular risk and the metabolic syndrome. Metab Syndr Relat Disord 2006, 4:252–260.CrossRefPubMedGoogle Scholar
  11. 11.
    Grundy SM: Metabolic syndrome: connecting and reconciling ­cardiovascular and diabetes worlds. J Am Coll Cardiol 2006, 47:1093–1100.CrossRefPubMedGoogle Scholar
  12. 12.
    Cameron AJ, Magliano DJ, Zimmet PZ, et al.: The metabolic ­syndrome as a tool for predicting future diabetes: the AusDiab study. J Intern Med 2008, 264:177–186.CrossRefPubMedGoogle Scholar
  13. 13.
    Ford ES, Li C, Sattar N: Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008, 31:1898–1904.CrossRefPubMedGoogle Scholar
  14. 14.
    Alexander CM, Landsman PB, Grundy SM: Metabolic syndrome and hyperglycemia: congruence and divergence. Am J Cardiol 2006, 98:982–985.CrossRefPubMedGoogle Scholar
  15. 15.
    Wilson PW, D’Agostino RB, Parise H, et al.: Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112:3066–3072.CrossRefPubMedGoogle Scholar
  16. 16.
    Lorenzo C, Okoloise M, Williams K, et al.: The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study. Diabetes Care 2003, 26:3153–3159.CrossRefPubMedGoogle Scholar
  17. 17.
    Ford ES: Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005, 28:1769–1778.CrossRefPubMedGoogle Scholar
  18. 18.
    Wannamethee SG, Shaper AG, Lennon L, Morris RW: Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005, 165:2644–2650.CrossRefPubMedGoogle Scholar
  19. 19.
    Rutter MK, Meigs JB, Sullivan LM, et al.: Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes 2005, 54:3252–3257.CrossRefPubMedGoogle Scholar
  20. 20.
    Wannamethee SG: The metabolic syndrome and cardiovascular risk in the British Regional Heart Study. Int J Obes 2008, 32(Suppl 2):S25–29.CrossRefGoogle Scholar
  21. 21.
    Kahn R: Metabolic syndrome—what is the clinical usefulness? Lancet 2008, 371: 1892–1893.CrossRefPubMedGoogle Scholar
  22. 22.
    Sattar N, McConnachie A, Shaper AG, et al.: Can metabolic ­syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008, 371:1927–1935.CrossRefPubMedGoogle Scholar
  23. 23.
    Malik S, Wong ND, Franklin SS, et al.: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004, 110:1245–1250.CrossRefPubMedGoogle Scholar
  24. 24.
    Lawlor DA, Lean M, Sattar N: ABC of obesity: obesity and vascular disease. BMJ 2006, 333:1060–1063.CrossRefPubMedGoogle Scholar
  25. 25.
    Despres JP, Lemieux I: Abdominal obesity and metabolic syndrome. Nature 2006, 444:881–887.CrossRefPubMedGoogle Scholar
  26. 26.
    Sundstrom J, Riserus U, Byberg L, et al.: Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006, 332:878–882.CrossRefPubMedGoogle Scholar
  27. 27.
    Stern MP, Fatehi P, Williams K, Haffner SM: Predicting future cardiovascular disease: do we need the oral glucose tolerance test? Diabetes Care 2002, 25:1851–1856.CrossRefPubMedGoogle Scholar
  28. 28.
    Najarian RM, Sullivan LM, Kannel WB, et al.: Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch Intern Med 2006, 166:106–111.CrossRefPubMedGoogle Scholar
  29. 29.
    Rutter MK, Meigs JB, Wilson PW: Cardiovascular risk and the metabolic syndrome. Metab Syndr Relat Disord 2006, 4:252–260.CrossRefPubMedGoogle Scholar
  30. 30.
    Sundstrom J, Vallhagen E, Riserus U, et al.: Risk associated with the metabolic syndrome versus the sum of its individual components. Diabetes Care 2006, 29:1673–1674.CrossRefPubMedGoogle Scholar
  31. 31.
    Orchard TJ, Temprosa M, Goldberg R, et al.: The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005, 142:611–619.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Adrian Cameron
    • 1
  • Jonathan Shaw
    • 1
  1. 1.Epidemiology and Clinical DiabetesBaker IDI Heart and Diabetes InstituteMelbourneAustralia

Personalised recommendations